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Abstract
Objective There is an urgent need for reliable and universally
applicable outcome measures for children with mitochondrial
diseases. In this study, we aimed to adapt the currently avail-
able Newcastle Paediatric Mitochondrial Disease Scale
(NPMDS) to the International Paediatric Mitochondrial
Disease Scale (IPMDS) during a Delphi-based process with
input from international collaborators, patients and care-
takers, as well as a pilot reliability study in eight patients.
Subsequently, we aimed to test the feasibility, construct valid-
ity and reliability of the IPMDS in a multicentre study.
Methods A clinically, biochemically and genetically hetero-
geneous group of 17 patients (age 1.6–16 years) from five
different expert centres from four different continents were
evaluated in this study.
Results The feasibility of the IPMDS was good, as indicated
by a low number of missing items (4 %) and the positive
evaluation of patients, parents and users. Principal component
analysis of our small sample identified three factors, which
explained 57.9 % of the variance. Good construct validity
was found using hypothesis testing. The overall interrater re-
liability was good [median intraclass correlation coefficient
for agreement between raters (ICCagreement) 0.85; range
0.23–0.99).
Conclusion In conclusion, we suggest using the IPMDS for
assessing natural history in children with mitochondrial
Communicated by: Carlo Dionisi-Vici
Electronic supplementary material The online version of this article
(doi:10.1007/s10545-016-9948-7) contains supplementary material,
which is available to authorized users.
* Saskia Koene
Saskia.koene@radboudumc.nl
1 Radboudn Center for Mitochondrial Medicine at the Department of
Paediatrics, Radboudumc, Geert Grooteplein 10. 6500 HB, PO BOX
9101, Nijmegen, The Netherlands
2 Department of Health Evidence, Radboudumc,
Nijmegen, The Netherlands
3 Steve Biko Academic Hospital, Ludwig-Maximilians-of Pretoria,
Pretoria, South Africa
4 Department of Paediatrics & Adolescent Medicine, University of
Hong Kong, Hong Kong, Hong Kong
5 Department of Neurology, ErasmusMC, Rotterdam, The Netherlands
6 Department of Pediatric Neurology and Developmental Medicine,
Dr. v. Hauner Children’s Hospital, Ludwig-Maximilians-University,
Munich, Germany
7 Department of Neurology, Friedrich-Baur-Institute,
Ludwig-Maximilians-University, Munich, Germany
8 German Center for Neurodegenerative Diseases (DZNE),
Munich, Germany
9 Munich Cluster for Systems Neurology (SyNergy),
Munich, Germany
10 Division of Human Genetics, Department of Pediatrics, The
Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
11 Department of Pediatrics, University of Pennsylvania Perelman
School of Medicine, Philadelphia, PA 19104, USA
12 Wellcome Trust Centre for Mitochondrial Research Newcastle,
Newcastle upon Tyne, UK
13 Department of Rehabilitation, Radboudumc,
Nijmegen, The Netherlands
J Inherit Metab Dis (2016) 39:705–712
DOI 10.1007/s10545-016-9948-7
diseases. These data should be used to further explore con-
struct validity of the IPMDS and to set age limits. In parallel,
responsiveness and the minimal clinically important differ-
ence should be studied to facilitate sample size calculations
in future clinical trials.
Introduction
Mitochondrial diseases (MD) are the most prevalent inherited
metabolic diseases, with an incidence of ∼1:5000 live births
(Schaefer et al. 2004). Since mitochondria are present in al-
most all cells, theoretically, symptoms can arise from every
organ. The most commonly affected organs and tissues in-
clude the brain, eye, heart, and skeletal muscle (Koopman
et al. 2012). There is enormous variability in the pattern of
affected organs and degree of disability experienced. Whereas
some children with MD thrive in mainstream school and live
well into adult life, others follow a more rapidly progressive
course and die in the neonatal period or function at a low level,
barely interacting with their environment.
Currently, there is no cure for MD, but there are some
promising results of pharmacological interventions in cells
and animals, and the prospects for randomised clinical trials
of novel and repurposed pharmaceuticals are increasing
(Koene and Smeitink 2009; Wenz 2009; Viscomi et al. 2011,
2015; Koopman et al. 2012; Blanchet et al. 2015; Peng et al.
2015). Outcome measures that are valid, reliable, sensitive
and clinically relevant are critical to the success of such trials,
but the heterogeneity and multisystemic nature of MD pose
significant challenges in choosing an appropriate, universally
applicable outcome measure (Koene et al. 2013a). To be able
to measure disease severity and progression within the full
range of the phenotypic spectrum, a combination of objective,
subjective, functional and biochemical end points will proba-
bly be necessary.
An MD-specific follow-up tool for use with children al-
ready exists: the Newcastle Paediatric Mitochondrial Disease
Scale (NPMDS) (Phoenix et al. 2006). This scale was origi-
nally designed to be a concise and pragmatic clinical tool to
monitor the biophysical markers of disease progression.
Although the NPMDS fits this purpose from a natural disease
course perspective, it was not designed as an end-point instru-
ment and probably lacks a sufficient level of detail required for
this purpose in clinical trials. Moreover, the scale was not
developed to measure the clinically relevant concept of func-
tional disability (Phoenix et al. 2006).
In this study, we aimed to adapt the NPMDS to a more
clinically relevant and detailed scoring system for future clin-
ical trials in paediatric patients with MD, thus creating the
International Paediatric Mitochondrial Disease Scale
(IPMDS), which should cover more symptoms indicated by
patients and parents as Bburdensome,^ such as tiredness and
lack of energy, behavioural problems and depression (Koene
et al. 2013b). We also aimed to include a functional domain to
quantify changes in a child’s motor abilities, since clinically
relevant changes in motor function are not always equally
reflected by changes in muscle power or tone and vice versa
(Abel et al. 2003; Beenakker et al. 2005; Parreira et al. 2010).
After a Delphi-based development process, we tested the con-
struct validity and reliability (interrater, intrarater and test–
retest) by field testing in several expert international centres.
Methods
The IPMDS was developed during a Delphi-based process by
consulting patients, parents and MD experts. After the pilot
reliability test, the scale was further optimised for subsequent
testing in five expert centres. All raters received both written
and video instructions. At each centre, two to four randomly
selected patients were assessed by three to four physicians
subsequently to evaluate interrater reliability. Construct valid-
ity was tested using factor analysis and by hypothesis testing.
In a subset of patients within these studies, test–retest reliabil-
ity and intrarater reliability was tested. For a more detailed
description of the methods, we refer to supplementary file 1.
This study was conducted in all indicated countries after
approval from the regional Medical Research Ethics
Committee (MREC NL.44833.091.13). In accordance with
the Declaration of Helsinki, written informed consent was
obtained from each participant or his/her legal guardian(s).
Statistics
Because of the relatively small number of patients in our
study, we used nonparametric tests for analyses and report
medians and ranges. Parent and patient experiences were
assessed for each patient individually. From a rater perspec-
tive, the number of blank items was counted to test feasibility.
Factor analysis was used to explain the variance–covariance
matrix for data in terms of relationships between a much
smaller number of unobserved variables, called factors. We
used data from the rater with the least missing data, and miss-
ing items were replaced using the mean of the other three
raters. We removed items for which <80 % was completed,
including items that could be assessed only when the child
was >6 years old (hopping, running, and rotating) and in case
the child was unable to report complaints, such as headache,
gastroesophageal reflux, muscle pain, vibration or subtle
touch at physical examination. Items with little variance (less
than two items score 1 or more) were also removed for the
factor analysis. Principal component analysis (PCA) was used
as the extraction method for factors. The orthogonal rotation
(varimax) with Kaiser’s normalisation was used to simplify
the interpretation of factors. The number of factors extracted
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was based on Eigen values >1. Sampling adequacy was deter-
mined using the Kaiser-Meyer-Olkin (KMO) measure. In ad-
dition, Bartlett’s test of sphericity was applied to test whether
correlations between items were sufficiently large for PCA.
The percentage of variance explained by each factor is also
presented. Sum scores for the factors were calculated using
clinically suitable items. Cronbach’s alpha was calculated as a
measure of internal consistency of each constructed factor.
The difference between patients with mild and with severe
disease (median value rated by physicians) for these sum
scores was tested using the Mann–Whitney U test.
We used hypothesis testing to assess construct validity.
Since all mentioned hypotheses involved two measurements
of the same construct, we aimed at moderate to good correla-
tions (ρ = 0.4–0.79). We used Spearman’s correlation coeffi-
cients to correlate between continuous or interval variables
(IPMDS and its subdomains and functional parameters). The
mean raters’ score in each patient was used to calculate the
correlation. Interrater reliability between physicians within
one centre seeing one patient was calculated using intraclass
correlation coefficient for agreement between raters
(ICCagreement). Intrarater reliability within two physicians
was calculated using ICCagreement between each rater’s scores.
Test–retest reliability was calculated using ICCagreement be-
tween scores. An ICCagreement ≥ 0.7 was used as Bacceptable^
(Vet et al. 2011).
We used a p value of 0.05 for statistical significance.
Correlation coefficients were interpreted in accordance with
the guidelines provided at the BMJ website (http://www.bmj.
com/about-bmj/resources-readers/publications/statistics-
square-one/11-correlation-and-regression). All analyses were
performed using IBM’s SPSS Statistics 22.0.0.1.
Results
Cohort description
A clinically and genetically heterogeneous cohort of 17 chil-
dren aged 1.6–16 years from five expert centres participated in
this study (supplementary Table 4A). Rater details are present-
ed in supplementary document 4B.
Scale description
After our Delphi-based process, the IPMDS consists of 61
items in three domains: 23 in Domain 1 (subjective com-
plaints and symptoms; obtained by interviewing parents);
25 in Domain 2 (physical examination; obtained by phys-
ical examination) and 13 in Domain 3 (functional assess-
ment; obtained by physical/motor function evaluation).
The final scale and the manual are presented in supplemen-
tary documents 2 and 3.
Table 1 Factor analysis: factor loadings for individual items. Based
on clinical communalities between items, we composed three factors
(in bold) including 32 of the 49 items
Factor Basic
functioning
Eating and
digesting
Abnormalities
at neurological
examination
3.05 Sitting 0.926
3.11 Reaching 0.916
3.12 Grasping 0.901
1.13 Communicating 0.871
3.07 Standing 0.875
3.04 Sitting up 0.867
2.18 Hypertonia 0.848
3.08 Walking 0.847
3.06 Standing up 0.843
3.02 Head control 0.831
3.03 Rolling over 0.821
2.20 Rigidity 0.808
3.01 Communication 0.772 0.513
1.22a Continence day 0.592
1.18 Cognitive 0.547 0.486
2.11 Prox muscle 0.408 0.614
1.11 Swallowing 0.894
1.10 Chewing 0.536 0.764
1.14 Vomiting 0.74 0.476
2.01 Growth 0.507 −0.405
1.16 Constipation −0.49
2.02 Weight −0.404 0.448
2.08 Eye movements −0.698
2.16 Tremor −0.628
2.13 Hypokinesia 0.745 0.568
1.01 Response 0.543
2.19 Hypotonia 0.525
2.15 Ataxia −0.511
1.23a Strabismus −0.498
2.14 Abnormal movement 0.69 −0.496
1.12 Hearing 0.403 0.494
2.17 Reflexes 0.419
1.22b Continence night 0.75
2.07 Strabismus 0.741
2.10 Vision 0.717
1.02 Exercise 0.616
1.09 Infections
1.04 Tired
1.23b Ptosis
1.06 Epilepsy
1.21 Breathing
2.06 Ptosis
Only factor loadings > 0.4 are presented
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Feasibility
The average time to complete the IPMDSwas 35min; 96% of
all items (85–100 %) relevant to the patient based on age and/
or mental capacities was completed. Sixteen (patients and
their) parents filled out the feasibility questionnaire. All pa-
tients and parents indicated that the number of questions, the
burden of the physical examination to the child, the duration
of the interview, physical examination and the total time bur-
den were just right or could be (much) longer. The parents of a
2-year-old patient experienced difficulties in translating the
questions to the situation of a toddler. This was not reflected
in the number of missing items for toddlers (94 %; 91–97 %)
and in the interrater reliability for the first and the third domain
(ICCagreement 0.86 versus 0.74 and 0.96 versus 0.97, respec-
tively, for toddlers versus all children). The interrater reliabil-
ity of the second domain was low in toddlers compared with
the whole cohort (ICCagreement 0.39 versus 0.81).
Factor analysis
A total of 44 of 61 items was included in the factor analysis.
Based on factor loadings and communalities, we were able to
include 32 of the 49 items in one of the factors (Table 1). Items
with little variance were removed (1.17 diarrhoea, 2.03 alert-
ness, 2.04 breathing, 2.09 nystagmus). Sample adequacy of
the factor analysis was sufficient for all items within the
IPMDS (KMO 0.51). Bartlett’s tests of sphericity indicated
that correlation between items was sufficiently large for
PCA (p <0.001).We identified three factors (Tables 1 and 2),
naming them based on items they contained: 1, basic func-
tioning (31.1 % of explained variance); 2, eating and digesting
(14.1 % of the explained variance); 3, abnormalities at neuro-
logical examination (12.7 % of explained variance). The in-
ternal consistency of these factors was good for factor 1
(Cronbach’s alpha = 0.97), acceptable for factor 2
(Cronbach’s alpha = 0.76) and poor for factor 3 (Cronbach’s
alpha = 0.16). The total percentage of explained variance by
the three factors was 57.9 %. Spearman’s correlation coeffi-
cients between factors (Table 3) indicate that all factors repre-
sent a unique identity.
Construct validity
We hypothesised that patients with a severe general MD se-
verity would have higher median score on extracted factors
compared with patients with mild disease (Table 4). This hy-
pothesis was confirmed for factor 1 (basic functioning;
p = 0.01; n = 13) but not for factors 2 (eating and digesting)
and 3 (abnormalities at neurological examination (p = 0.07
and 0.28, respectively). In Table 5 correlation coefficients be-
tween factors, IPMDStotal, IPMDS subdomains, severity
scores, Pediatric Evaluation of Disability Index (PEDI) and
the NPMDS are presented. Correlation between the basic
functioning factor and PEDI, rating the functional perfor-
mance and abilities of the child, was excellent (ρ = 0.90;
p < 0.001); correlation between the factor abnormalities at
neurological examination and rater-rated severity of abnor-
malities at general physical examination was weak (ρ = 0.23;
p < 0.05). All predefined hypotheses used for construct valid-
ity testing indeed had good to excellent correlations (ρ = 0.64-
0.90; Table 5).
Reliability
Table 6 shows the interrater reliability of the IPMDS. Inter-
rater reliability of sum scores of the three factors was good
(ICCagreement = 0.98, 0.94 and 0.78 for basic functioning, eat-
ing and digesting, and abnormalities at neurological examina-
tion, respectively). The median ICCagreement of all individual
Table 2 Factor analysis: factors and their characteristics resulting from factor analysis of items within the IPMDS
Factor No. items in
factor
Eigenvalues Explained
variance (%)
Explained variance
(%; total)
Cronbach’s alpha
Basic functioning 16 14.3 31.1 31.1 0.97
Eating and digesting 6 5.2 14.1 45.2 0.76
Abnormalities at neurological examination 10 4.8 12.7 57.9 0.16
Table 3 Factor analysis:
Spearman’s correlation
coefficients between sum scores
of factors
Factor Basic
functioning
Eating and
digesting
Abnormalities at
neurological examination
Basic functioning 1.00
Eating and digesting 0.47* 1.00
Abnormalities at neurological examination 0.42* 0.13 1.00
*Significant at a 0.01 level.
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items within the IPMDS was 0.85 (0.23–0.99), 0.81 (0.44–
0.98) of the first domain, 0.74 (0.23–0.93) of the second do-
main and 0.97 (0.93–0.99) in the third domain (Table 6).
Small pilot studies on video-rated intra-rater and test–retest
reliability showed good intrarater reliability (median
ICCagreement = 0.87; n = 4). Test–retest reliability by telephone
interview of the first domain after 1 week was excellent when
performed by the same rater (median ICCagreement = 1.0 in 15
of 16 items with variance; n = 4) but inconsistent when per-
formed by a different rater (median ICCagreement 0.73; n =4 ).
Discussion
The IPMDS, a multidimensional scale rating clinically rele-
vant aspects of MD in children, was developed during a
Delphi-based process by an international expert team in close
dialogue with patients and their parents. Designing a scale for
general MD severity is challenging because of the wide vari-
ability in symptoms and (dis)abilities seen in children with
MD. This complexity is reflected in the high number of items
included in the IPMDS and the breath of items reflecting the
Table 4 Factor analysis: median and IQR of factor sum scores for patient groups within different disease stages and difference between groups
Factor Mild disease
(n = 3)
Severe disease
(n = 10)
Difference between patients mild and severe disease
Median IQR Median IQR P value
Basic functioning 0 (0–0) 43 (14–56) 0.01
Eating and digesting 2 (0–2) 10 (5–16) 0.08
Abnormalities at neurological examination 3 (1–3) 10 (2–12) 0.29
IQR interquartile range
Table 5 Construct validity of the IPMDS: correlations between tests
Factor IPMDS
total
IPMDS
Domain 1
IPMDS
Domain 2
IPMDS
Domain 3
Sum of basic
functioning
Sum score of
eating and
digesting
Sum score of
abnormalities at
neurological
examination
General disease severity (P) 0.806** 0.480** 0.558** 0.725** 0.658** 0.426* 0.038
General disease severity (R) 0.642** 0.529** 0.744** 0.810** 0.786** 0.476** 0.237*
Severity of abnormalities at physical examination (R) 0.853** 0.536** 0.750** 0.839** 0.803** 0.519** 0.226*
Functional limitations (P) 0.665** 0.500** 0.563** 0.779** 0.740** 00.328 0.135
Functional limitations (R) 0.817** 0.573** 0.719** 0.809** 0.760** 0.381** 0.293**
PEDI total 0.912** −0.784** −0.773** −0.890** −0.904** −0.668** −0.283
PEDI self-care −0.916** −0.767** −0.767** −0.881** −0.882** −0.684** −0.263
PEDI mobility −0.918** −0.749** −0.797** −0.917** −0.901** −0.588** −0.243
PEDI social function −0.673** −0.750** −0.569** −0.662** −0.713** −0.552** −0.297
NPMDS total 0.840** 0.475** 0.771** 0.836** 0.816** 0.572** 0.183
NPMDS Section 1 0.887** 0.512** 0.777** 0.865** 0.882** 0.606** 0.27
NPMDS Section 2 −00.144 −0.172 −0.117 0.100 00.029 −00.133 −0.146
NPMDS Section 3 0.854** 0.597** 0.855** 0.773** 0.657** 0.676** 0.196
IPMDS total 1.000 0.836** 0.929** 0.907** 0.884** 0.557** 0.553**
IPMDS Domain 1 0.836** 1.000 0.551** 0.551** 0.750** 0.632** 0.439**
IPMDS Domain 2 0.929** 0.551** 1.000 0.883** 0.835** 0.615** 0.529**
IPMDS Domain 3 0.907** 0.551** 0.883** 1.000 0.931** 0.528** 0.426**
Correlation coeffients of total and subscores of the IPMDS with subjective disease severity as rated by parents and physicians (mean), with the NPMDS
total and subdomain scores and with the PEDI total and subdomains scores, Bolded data represent correlations used for construct validity hypothesis
testing
PEDI Pediatric Evaluation of Disability Index, IPMDS International Paediatric Mitochondrial Disease Scale, MPMDS Newcastle Paediatric
Mitochondrial Disease Scale, P Parents, R Rater
*Significant at 0.05, **significant at 0.01 level
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multisystemic nature of the disease. Critically evaluating psy-
chometric properties in 17 children in five international expert
centres, we found good feasibility and an acceptable construct
validity and reliability.
We found a suboptimal interrater reliability for some IPMDS
items, mainly within the physical examination domain. This is in
agreement with literature reports in which low interrater agree-
ment in gait analysis, neurological reflexes and classification of
movement disorders has been reported (Miller and Johnston
2005; Singerman and Lee 2008; Bella et al. 2012; Beghi et al.
2014). Lower agreement was observed in patients with develop-
mental delay (Hsue et al. 2014) and in general neurologists com-
paredwith residents and experts (Beghi et al. 2014). Our teams of
raters reported difficulties in agreeing on hypertonia and rigidity.
This might be explained by the mixed picture of pyramidal and
extrapyramidal syndromes in patients with MD (and more spe-
cifically in patients with Leigh syndrome, which represents about
half of the cases included in this study). Moreover, tone is highly
dependent on the child’s level of alertness, emotional state, fa-
tigue level posture (Sanger et al. 2003), and changes in tone
during the day were frequently reported by our raters.
Although the IPMDSwas adopted from the NPMDS, there
are important differences. First, the NPMDS consists of 26
items with mostly a 0–3 scale, whereas the IPMDS consists
of 61 items, mostly on a 0–5 scale. For example, the Bfeeding^
Table 6 Interrater reliability of items on the International Paediatric
Mitochondrial Disease Scale (IPMDS)
Factor Basic
functioning
ICCagreement No. = number
of patients
Feasibility
1.01 Response to
environment
0.670 17
1.02 Exercise capacity 0.701 13 x
1.03 Walking distance 0.847 16
1.04 Tiredness 0.780 16
1.05 Depressed 0.847 12 x
1.06 Epilepsy 0.855 17
1.07 Headache 0.931 12 x
1.08 Muscle pain 0.575 12 x
1.09 Infections 0.581 17
1.10 Chewing 0.942 17
1.11 Swallowing 0.886 17
1.12 Hearing 0.762 17
1.13 Communicating 0.953 16
1.14 Vomiting 0.972 17
1.15 Gastroesophageal
reflux
0.962 15
1.16 Constipation 0.833 17
1.17 Diarrhoea 0.976 16
1.18 Cognitive
functioning
0.635 15
1.19 Behavioural
problems
0.443 16
1.20 Autistic features 0.661 11 x
1.21 Breathing subjective 0.934 15
1.22a Continence day 0.725 14
1.22b Continence night 0.725 14
1.23a Strabismuswhen tired 0.736 15
1.23b Ptosis when tired 0.573 15
1.23c Dysarthria when tired 0.838 13 x
2.01 Growth 0.944 15
2.02 Weight 0.751 15
2.03 Alertness NV 17
2.04 Breathing 0.740 17
2.05 Dysarthria 0.901 12 x
2.06 Ptosis 0.553 17
2.07 Strabismus 0.82 16
2.08 Eye movements 0.691 16
2.09 Nystagmus 0.925 16
2.10 Vision 0.343 11 x
2.11 Proximal muscle
power
0.913 15
2.12 Distal muscle power 0.738 14
2.13 Hypokinesia 0.306 14
2.14 Abnormal
movements
0.884 16
2.15 Ataxia 0.858 14
2.16 Tremor 0.864 15
2.17 Reflexes 0.312 16
2.18 Hypertonia 0.649 17
Table 6 (continued)
Factor Basic
functioning
ICCagreement No. = number
of patients
Feasibility
2.19 Hypotonia 0.470 17
2.20 Rigitidy 0.597 17
2.21a Vibration 0.231 11 x
2.21b Subtle touch NV 11 x
3.01 Communicating 0.957 17
3.02 Head control 0.983 17
3.03 Rolling over 0.985 16
3.04 Sitting up 0.963 17
3.05 Sitting up 0.984 17
3.06 Standing up 0.979 17
3.07 Standing 0.974 17
3.08 Walking 0.989 17
3.09 Running 0.968 13 Only
>6 years
3.10 Hopping 0.954 13 Only
>6 years
3.11 Reaching 0.964 16
3.12 Grasping 0.949 16
3.13 Rotating 0.985 14 Only
>6 years
ICCagreement median intraclass correlation coefficient for agreement be-
tween raters per IPMDS item: ≥ 0.7 good agreement are in bold; ≤0.3 poor
agreement is in italic x feasible in <80 % of participants, NV no variance
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item in the NPMDS was replaced by items on chewing (in-
cluding ability to chew, e.g. bread crusts and meat),
swallowing (including difficulties/choking with dry food or
fluids) and vomiting. The IPMDS therefore takes longer to
execute (on average: 35 min) but is considerably more de-
tailed. Although the burden to the patient doesn’t seem to be
unacceptably high—as indicated by the positive evaluation of
the IPMDS by patients and parents—the feasibility of
performing the IPMDS as part of daily care at the outpatient
clinic, a central tenet of developing the NPMDS, is question-
able. Secondly, since behavioural problems and speech and
language problems were among the most burdensome com-
plaints experienced by patients and their parents (Koene et al.
2013b), we included these items in the complaints and symp-
toms and in the functional (communication) domain of the
IPMDS. Thirdly, the IPMDS has a functional domain that is
expected to be the most objective, responsive and relevant
item for natural history and intervention studies. Lastly, we
use the same scoring system for all ages (with the exception
of some functional items). Although this complicates the anal-
ysis of very young children—which was also difficult in the
NPMDS for 0- to 24-month-olds since newborns differ from
toddlers—longitudinal analysis is more meaningful when
using the same scoring system. These differences are illustrat-
ed by the lack of a statistically significant correlation between
the IPMDS and the NPMDS.
Strengths of our study include: following applicable guide-
lines provided by the US Food and Drug administration
(Administration 2009) for designing the IPMDS, the expert
international team providing input to IPMDS content and val-
idation in five expert international centres in a heterogeneous
group of children with MD. However, since we aimed at a
scale covering the whole phenotypic spectrum of MD, the
IPMDS may contain many irrelevant items for individual pa-
tients. Disadvantages of the study include the undetermined
influence of normal development on the score, and relatively
small study population per centre. The small population also
affects the validity of the factor analysis, so exploratory factor
analysis should be repeated when more data is obtained.
Lastly, eight out of 17 patients in this study had Leigh syn-
drome, limiting the generalizability of results.
Based on our data, we suggest using the IPMDS for
assessing natural history in a larger and more heterogeneous
population of children with MD. Since the IPMDS also in-
cludes subjective and functional parameters, this natural his-
tory data will not only provide clinicians with relevant infor-
mation about which patients will be at risk to develop, for
example, cardiomyopathy or renal failure. However, it will
provide relevant prognostic information to patients and their
parents. Data collected in these natural history studies should
undergo another exploratory factor analysis to obtain further
evidence for construct validity of the IPMDS. (We kindly
invite you to upload your IPMDS scoring sheets
anonymously on our website http://www.rcmm.info/ipmds).
Besides, such data will facilitate setting age limits for the
IPMDS, since both the number of missing items and the
interrater reliability indicate that adaptations are necessary
for babies and toddlers.
The aim of this study was to adapt the NPMDS to a more
clinically relevant and detailed scoring system for future clin-
ical trials in paediatric patients withMD. This is the first report
on the rational for IPMDS development, including a first im-
pression of the feasibility, reliability and validity of the current
scale. Using the anonymously uploaded data from internation-
al collaborators, as well as more detailed studies on the psy-
chometric properties in larger and more heterogeneous popu-
lations with a larger age range, we aim to optimise the scale
further. Examples of future research questions include: Is the
interrater reliability of Domain 2 acceptable after optimising
the instructions in the manual? What is the minimal clinically
important difference (Wright et al. 2012)? What is the influ-
ence of normal development and growth on the reliability and
construct validity of the IPMDS, including the possible re-
quirement of age-specific scales?
In conclusion, the IPMDS seems a robust tool for the
follow-up of children with MD. Data obtained in larger and
more heterogeneous populations included in natural history
studies, in combination with a close dialogue with parents
regarding the minimal clinically important difference, will
further substantiate the instrument for clinical trials.
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